Dr. David Haefliger | Pharmacology | Best Researcher Award

Published on by Shen Awards

Dr. David Haefliger | Pharmacology | Best Researcher Award

Dr. David Haefliger, CHUV, Switzerland

Dr. David Haefliger is a distinguished expert in pharmacology, recognized for his groundbreaking research and contributions to the field. With a strong background in drug interactions and therapeutic efficacy, Dr. Haefliger’s work has significantly advanced the understanding of pharmacological mechanisms and their clinical applications. His research is widely published in leading journals and has been instrumental in shaping contemporary practices in pharmacology. As a recipient of the Best Researcher Award, Dr. Haefliger continues to drive innovation and excellence in his field, demonstrating an unwavering commitment to advancing medical science and improving patient outcomes.

Profile

Scoopus

Education 

Dr. David Haefliger has an extensive educational and professional background in the medical field. He earned his Bachelor’s degree in Medicine in June 2012 and his Master’s degree in Medicine in June 2015, both from the University of Lausanne, Switzerland. In addition to his foundational degrees, he completed the Swiss Board Examination in General Internal Medicine in June 2019, and he is an Advanced Cardiovascular Life Support Provider, certified in October 2016. Most recently, in 2024, Dr. Haefliger obtained a Certificate of Advanced Studies in Clinical Research from the University of Lausanne, further solidifying his expertise and commitment to advancing clinical research.

Proffesional Experience

Since February 2022, Dr. David Haefliger has been working in the Service of Clinical Pharmacology at the Department of Medicine, University Hospital Lausanne, Switzerland. Prior to this role, he served in the Service of Infectious Diseases at the University Hospital Lausanne from November 2019 to October 2021. Dr. Haefliger also gained valuable experience in the Intensive Care Unit at Fribourg Hospital from November 2018 to October 2019. His career began in Internal Medicine at Fribourg Hospital, where he worked from November 2015 to October 2018.

 

Publication Top Notes

  • Haefliger D, Chehade H, Livio F, Rodrigues-Veiga V, Diezi L, Marzolini C. Vancomycin Dosing Strategy for the Treatment of Peritonitis in a Child on Automated Peritoneal Dialysis: A First Pediatric Case Report. Semin Dial. 2024.
  • Dao K, Buettcher M, Golhen K, et al. Novel Patient-Friendly Orodispersible Formulation of Ivermectin is Associated With Enhanced Palatability, Controlled Absorption, and Less Variability: High Potential for Pediatric Use. J Clin Pharmacol. 2024.
  • Dao K, Shechtman S, Weber-Schoendorfer C, et al. Use of GLP-1 Receptor Agonists in Early Pregnancy and Reproductive Safety: A Multicentre, Observational, Prospective Cohort Study Based on the Databases of Six Teratology Information Services. BMJ Open. 2024.
  • Grütter S, Haefliger D, Wuerzner G, Yerly P, Bouchardy J, Rutz T. The Deleterious Consequences of a Nonsteroidal Anti-inflammatory Drug in an Eisenmenger Patient. CJC Pediatr Congenit Heart Dis. 2023.
  • Haefliger D, Marzolini C, Lamoth F, Pabst T, Buclin T, Livio F. Clinically Relevant Bidirectional Drug-Drug Interaction Between Midostaurin and Voriconazole. Br J Clin Pharmacol. 2023.
  • Haefliger D, Livio F. Pharmacothérapie – Nouveaux Médicaments et Vaccins Disponibles en 2022 [Pharmacotherapy: New Drugs and Vaccines in 2022]. Rev Med Suisse. 2023.
  • Desgranges F, Tadini E, Munting A, et al. Post-COVID-19 Syndrome in Outpatients: A Cohort Study. J Gen Intern Med. 2022.
  • Regina J, Papadimitriou-Olivgeris M, Burger R, et al. Epidemiology, Risk Factors, and Clinical Course of SARS-CoV-2 Infected Patients in a Swiss University Hospital: An Observational Retrospective Study. PLoS One. 2020.
  • Grandjean T, Haefliger D, Arroyo D, Cook S. Coronary Sinus Reduction for the Treatment of Refractory Angina. Cardiovasc Med. 2018.
  • Haefliger D, Chuard C. Légionellose [Legionellosis]. Rev Med Suisse. 2017.

Articles with Acknowledgments (as a member of the RegCOVID Study Group):

  • Galperine T, Choi Y, Pagani JL, et al. Temporal Changes in Fecal Microbiota of Patients Infected with COVID-19: A Longitudinal Cohort. BMC Infect Dis. 2023.
  • COVID-19 Host Genetics Initiative. Mapping the Human Genetic Architecture of COVID-19. Nature. 2021.
  • Bibert S, Guex N, Lourenco J, et al. Transcriptomic Signature Differences Between SARS-CoV-2 and Influenza Virus Infected Patients. Front Immunol. 2021.

Shriyansh Srivastava | Pharmacology Award | Best Researcher Award

Published on by Shen Awards

Mr. Shriyansh Srivastava | Pharmacology Award | Best Researcher Award

Assistant Professor at Pharmacology Award, Galgotias University, India

Mr. Shriyansh Srivastava is a dedicated professional with a strong academic background and diverse expertise in the field of pharmacology and clinical research. Currently pursuing a PhD at Delhi Pharmaceutical Sciences and Research University, he previously completed his M. Pharm at ISF College of Pharmacy, where he achieved a CGPA of 8.54. With a B. Pharm from Dr. A.P.J. Abdul Kalam Technical University and a 12th-grade education from CRTS Vidya Mandir, Mr. Srivastava’s academic journey demonstrates his commitment to excellence. In addition to his academic achievements, Mr. Srivastava has been serving as an Assistant Professor at Galgotias University since August 31, 2021, focusing on the pharmaceutical field. He has attended various workshops and conferences, showcasing his dedication to continuous learning and professional development. His expertise includes operating advanced laboratory equipment such as the Langendroff Apparatus, fluorescent microscope, and centrifuge. He is also skilled in animal handling, histological studies, and using MS Office applications.

Professional Profiles:

Education:

Mr. Shriyansh Srivastava is currently pursuing a PhD in Pharmacology & Clinical Research at Delhi Pharmaceutical Sciences and Research University, New Delhi, India, from 2022 to the present. He completed his M. Pharm (Pharmacology) at ISF College of Pharmacy, Moga, Punjab, India, from 2019 to 2021, with a CGPA of 8.54. His B. Pharm was completed at Dr. A.P.J. Abdul Kalam Technical University, Lucknow, Uttar Pradesh, India, from 2014 to 2018, with a percentage of 74.82%. In 2013-2014, he completed his 12th grade at CRTS Vidya Mandir, Siswa, Maharajganj, Uttar Pradesh, India, with a percentage of 86.6%.

Professional Experience:

This information describes Mr. Shriyansh Srivastava’s current professional role as an Assistant Professor at Galgotias University. It specifies that he is part of the School of Medical and Allied Sciences, specifically in the Department of Pharmacy. The details include his start date, which is August 31, 2021, indicating the duration of his employment in this position. It also mentions his focus area, highlighting that his teaching and research activities are centered around the pharmaceutical field. Overall, this information provides an overview of his current professional responsibilities and academic focus within the university setting.

Award Participated:

Mr. Shriyansh Srivastava has actively participated in various workshops and conferences to enhance his professional knowledge and skills. He attended a workshop on advanced histopathological techniques using microtome, cryostat, and tissue processor in February 2021. He also presented at the International Conference on “Unlocking Challenges Innovations and Global Opportunities in Research Amidst COVID-19 Pandemic” in December 2020. Additionally, he participated in the 59th National Pharmacy Week 2020 organized by ISF College of Pharmacy, Moga, and attended a one-day international workshop on lung injury therapy in November 2019. He also participated in the 54th IHPA National conference on safe and effective medicine in September 2019 and the 31st Annual Conference of India Pharmacy Graduates Association in April 2017, showcasing his commitment to professional development and staying updated with the latest advancements in the field.

Skills:

Mr. Shriyansh Srivastava possesses a wide range of expertise in laboratory equipment and techniques. He is proficient in operating the Langendroff Apparatus, fluorescent microscope, centrifuge, non-invasive blood pressure apparatus, Eddy’s hot plate, plethysmometer, actophotometer, student organ bath, microtome, and cryostat. He also has experience in handling animals, particularly rats, mice, and guinea pigs. Additionally, he has a strong understanding of histological studies and is skilled in using MS Office applications (Word, Excel, PowerPoint). He is well-versed in safety requirements and laboratory management, ensuring a clean and safe workplace. Furthermore, he is knowledgeable about Windows operating systems and various application software such as ChemDraw, EndNote, and BioRender.

Publications:

  1. Unveiling the potential of proteomic and genetic signatures for precision therapeutics in lung cancer management
    • Authors: S Srivastava, N Jayaswal, S Kumar, PK Sharma, T Behl, A Khalid, …
    • Year: 2024
    • Citations: 7
    • Journal: Cellular Signalling 113, 110932
  2. The Global Monkeypox (Mpox) outbreak: a comprehensive review
    • Authors: S Srivastava, S Kumar, S Jain, A Mohanty, N Thapa, P Poudel, K Bhusal, …
    • Year: 2023
    • Citations: 7
    • Journal: Vaccines 11 (6), 1093
  3. Biodegradable electrospun scaffolds as an emerging tool for skin wound regeneration: A comprehensive review
    • Authors: D Sharma, S Srivastava, S Kumar, PK Sharma, R Hassani, HG Dailah, …
    • Year: 2023
    • Citations: 6
    • Journal: Pharmaceuticals 16 (2), 325
  4. Wnt/β-catenin antagonist pyrvinium rescues high dose isoproterenol induced cardiotoxicity in rats: Biochemical and immunohistological evidences
    • Authors: S Srivastava, S Yadav, G Singh, SS Bajwa
    • Year: 2022
    • Citations: 6
    • Journal: Chemico-Biological Interactions 358, 109902
  5. Evolution of β-catenin-independent Wnt–GSK3–mTOR signalling in regulation of energy metabolism in isoproterenol-induced cardiotoxicity model
    • Authors: S Srivastava, N Bagang, S Yadav, S Rajput, D Sharma, A Dahiya, …
    • Year: 2021
    • Citations: 5
    • Journal: Inflammation Research 70 (7), 743-747
  6. Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
    • Authors: S Dhoundiyal, S Srivastava, S Kumar, G Singh, S Ashique, R Pal, …
    • Year: 2024
    • Citations: 3
    • Journal: European Journal of Medical Research 29 (1), 26
  7. Emergence of Marburg virus: a global perspective on fatal outbreaks and clinical challenges
    • Authors: S Srivastava, D Sharma, R Rijal, S Adhikari, P Bashyal, JJ Barboza, …
    • Year: 2023
    • Citations: 3
    • Journal: Frontiers in Microbiology 14, 1239079
  8. Platelet‐rich plasma exhibits anti‐inflammatory effect and attenuates cardiomyocyte damage by reducing NF‐κB and enhancing VEGF expression in isoproterenol induced …
    • Authors: S Yadav, S Srivastava, G Singh
    • Year: 2022
    • Citations: 3
    • Journal: Environmental Toxicology 37 (4), 936-953
  9. Recent Nipah virus outbreak in India: lessons and imperatives
    • Authors: S Srivastava, N Deb, P Roy, V Jaiswal, S Sah, Y Pandey, …
    • Year: 2023
    • Citations: 1
    • Journal: Therapeutic Advances in Infectious Disease 10, 20499361231208535
  10. Significant progress in chikungunya Control: FDA approval of Ixchiq vaccine
    • Authors: S Srivastava, S Kumar, P Satapathy, KH Jaaaim, AH Hermis, R Mehta, …
    • Year: 2024
    • Journal: Clinical Infection in Practice, 100351